Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42

Rhea-AI Summary

Hemostemix (OTCQB: HMTXF) announced that Japan granted registration of the trademark "KNOW YOUR HEALTH" under International Registration No. 1744775 on October 22, 2025, covering Classes 1, 5, and 42.

The registration, issued via the Japanese Patent Office through the WIPO Madrid System, secures brand rights for stem-cell preparations, pharmaceutical/biological compositions including autologous ACP-01 uses, and scientific/clinical services in regenerative medicine. The company says this strengthens its IP position in Japan, aligns the mark with ongoing ACP-01 clinical/special-access programs for ischemic and cardiopulmonary indications, and supports licensing and collaboration opportunities in Japan's research market.

Positive

• Trademark granted in Japan on October 22, 2025
• Coverage across Classes 1, 5, 42 for stem-cell products and services
• Registration issued via Japanese Patent Office/WIPO Madrid System
• Supports potential licensing and co-development in Japan

Negative

• Trademark protects branding but is not a regulatory approval for ACP-01 therapies
• No binding commercial deals, revenue figures, or timelines disclosed

Calgary, Alberta--(Newsfile Corp. - October 22, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia, is pleased to announce that the Government of Japan has granted registration of its trademark "KNOW YOUR HEALTH", under International Registration No. 1744775, covering Classes 1, 5, and 42.

This registration secures Hemostemix's rights in Japan for the mark Know Your Health and its design, reinforcing the Company's intellectual property position and global branding strategy across regenerative medicine, biotechnology, and personalized health innovation.

Trademark Grant Details

• Registration Number: International Registration No. 1744775

• Mark: KNOW YOUR HEALTH

• Classes Covered:

  • Class 1: Chemicals and reagents for scientific and medical research, including stem cell preparations for use in regenerative medicine.

  • Class 5: Pharmaceutical and biological preparations, including autologous stem cell compositions for the treatment of peripheral vascular disease, critical limb ischemia, peripheral neuropathy, Class I-IV heart disease including angina, ischemic cardiomyopathy, and dilated cardiomyopathy, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary hypertension, and other diseases of ischemia.

  • Class 42: Scientific, clinical, and technological services in the field of regenerative medicine, including design, research, and development of cell-based therapies, diagnostics, and personalized health data platforms.

• Issuing Authority: Japanese Patent Office (via WIPO Madrid System)

Strategic Significance

1. Alignment with Clinical Programs: The trademark encompasses therapeutic areas currently available under right to try legislation or special access programs in various jurisdictions including Japan, of an ACP-01 treatment for patients suffering from angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia reinforcing the synergy between brand identity and pipeline.

2. Strengthened Global IP Portfolio: This registration extends Hemostemix's "Know Your Health" brand protection into Japan, one of the world's leading medical-research markets, further securing its intellectual property in regenerative medicine and personalized cell-therapy services.

3. Expanded Therapeutic Coverage: The inclusion of stem-cell preparations and therapies for a comprehensive range of ischemic and cardiopulmonary diseases reflects Hemostemix's leadership in developing autologous cell-based treatments for vascular and degenerative disorders.

4. Platform for Global Collaboration: Protection of "Know Your Health" under Classes 1, 5 and 42 allows Hemostemix to license, commercialize, and co-develop diagnostic and therapeutic innovations within Japan's regulatory framework for regenerative medicine.

CEO Commentary

"We are honoured that Japan has granted the 'Know Your Health' trademark across the full spectrum of our business-from stem-cell preparations and therapeutics to our diagnostic and research platforms. This registration validates our expanding global footprint and reflects our commitment to helping patients understand and improve their vascular, cardiac, and neurological health through autologous stem-cell therapy. Japan's recognition of our brand strengthens our capacity to partner with leading institutions and clinicians in Asia as we continue to advance ACP-01 and our broader regenerative-medicine pipeline."

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in eleven peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the grant of a trademark in Japan (Know Your Health) for the completion of the Treatment of angina, peripheral arterial disease, chronic limb threatening ischemia, ischemic cardiomyopathy, non-ischemic dilated cardiomyopathy, congestive heart failure, and total body ischemia with Angiogenic Cell Precursors (ACP-01) in furtherance of sales of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271450

FAQ

What did Hemostemix (HMTXF) announce on October 22, 2025 about its trademark in Japan?

Hemostemix announced Japan granted the "KNOW YOUR HEALTH" trademark, International Registration No. 1744775, covering Classes 1, 5, and 42.

Which product and services does the HMTXF trademark cover under Classes 1, 5, and 42 in Japan?

Class 1 covers stem-cell preparations and reagents; Class 5 covers pharmaceutical/biological autologous stem-cell compositions including ACP-01 indications; Class 42 covers scientific, clinical, and technological regenerative-medicine services.

Does the Japanese trademark grant mean ACP-01 has regulatory approval in Japan for HMTXF?

No. The registration secures branding and IP rights but is not a regulatory approval for clinical use of ACP-01.

How does the HMTXF trademark registration affect Hemostemix's ability to collaborate in Japan?

The company says the registration strengthens its IP position and enables potential licensing, commercialization, and co-development within Japan's regenerative-medicine framework.

Which authority issued Hemostemix's Japanese trademark for HMTXF?

The trademark was registered in Japan via the Japanese Patent Office through the WIPO Madrid System.